Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(8.81) per share which missed the analyst consensus estimate of $(6.12) by 43.95 percent. The company reported quarterly sales of $57.000 million which beat the analyst consensus estimate of $58.000 thousand by 98.18K percent.